文献速递关节外科骨质疏松与代谢性骨病

围手术期地舒单抗暴露与骨关节炎患者全髋/全膝关节置换术后翻修风险:注册数据链接研究

Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage study.
PubMed 文献 · Osteoporos Int · 2026-04-30

该回顾性队列研究基于Emilia-Romagna骨科假体植入物注册中心(RIPO)2011至2023年因骨关节炎行初次全髋或全膝关节置换的患者,比较围手术期地舒单抗与阿仑膦酸钠暴露后的翻修累积 incidence。全髋队列中两组翻修率无显著差异(Gray's p=0.623),全膝队列中地舒单抗组翻修累积 incidence 显著更高(Gray's p=0.002),主要由无菌性胫骨松动驱动。

要点

  • 全髋置换队列中地舒单抗与阿仑膦酸钠组翻修率无显著差异(Gray's p=0.623)。
  • 全膝置换队列中地舒单抗组翻修累积 incidence 显著高于阿仑膦酸钠组(Gray's p=0.002)。
  • 地舒单抗组翻修主要归因于无菌性胫骨松动,需谨慎解读且不 imply 因果关系。

核心结论

  • 围手术期地舒单抗暴露与全膝置换术后更高的翻修累积 incidence 相关,但与全髋置换术后翻修无显著关联。

研究设计与样本

  • 回顾性队列研究,使用Emilia-Romagna骨科假体植入物注册中心(RIPO)2011至2023年因骨关节炎行初次全髋或全膝关节置换的患者数据。

主要发现

  • 全髋队列:地舒单抗组129例中4例(3.1%)翻修,阿仑膦酸钠组922例中21例(2.3%)翻修,竞争风险分析无显著差异(Gray's p=0.623)。
  • 全膝队列:地舒单抗组117例中8例(6.8%)翻修,阿仑膦酸钠组940例中18例(1.9%)翻修,累积 incidence 差异显著(Gray's p=0.002)。
  • 地舒单抗组翻修主要由于无菌性胫骨松动。

关键数值与推荐

  • 围手术期暴露定义为术前或术后180天内至少一次地舒单抗或阿仑膦酸钠配药。
  • 主要结局为首次翻修,采用累积 incidence 函数分析,将死亡和移民作为竞争事件,组间比较用Gray's检验。

临床怎么用

  • 全膝置换围手术期使用地舒单抗的患者需关注无菌性胫骨松动及翻修风险,全髋置换中未观察到类似信号。

局限性

  • 观察性设计不能 imply 因果关系,发现应谨慎解读;作者指出需进一步研究抗骨吸收治疗与关节特异性生物力学因素的复杂交互。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoarthritis patients undergoing THA or TKA were studied to compare the cumulative incidence of revision after perioperative denosumab versus alendronate. Denosumab was not associated with differences in the incidence of revision after THA but was associated with a higher revision incidence after TKA, mainly driven by aseptic tibial loosening. BACKGROUND: Osteoarthritis is highly prevalent, and the number of total hip (THA) and knee arthroplasties (TKA) continues to rise. This study aimed to evaluate the risk of revision associated with perioperative exposure to denosumab versus alendronate in patients undergoing THA or TKA for osteoarthritis. METHODS: This retrospective cohort study used data from the Emilia-Romagna Registry of Orthopedic Prosthetic Implants (RIPO). Patients undergoing primary THA or TKA for osteoarthritis between 2011 and 2023 were included. Perioperative exposure was defined as at least one dispensing of denosumab or alendronate within 180 days before or after surgery. The primary outcome was first revision. Revision risk was analysed using cumulative incidence functions, treating death and emigration as competing events, and groups were compared using Gray's test. RESULTS: The THA cohort comprised 129 denosumab and 922 alendronate users. Revision occurred in 4 denosumab (3.1%) and 21 alendronate patients (2.3%); no significant difference was observed in competing risk analyses (Gray's p = 0.623). In the TKA cohort, 117 denosumab and 940 alendronate users were analysed. Here 8 denosumab patients (6.8%) and 18 alendronate patients (1.9%) required revision, with a significant difference in cumulative incidence (Gray's p = 0.002). Revisions in denosumab users were mainly due to aseptic tibial loosening. CONCLUSIONS: Perioperative denosumab exposure was associated with a higher cumulative incidence of revision after TKA in this cohort. These findings should be interpreted cautiously and do not imply causality. The observed pattern may reflect complex interactions between antiresorptive therapy and joint-specific biomechanical factors, which warrant further investigation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Ciaffi J, Bordini B, Cosentino M, et al. Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage study. Osteoporos Int. 2026. PMID: 42056270. doi:10.1007/s00198-026-08040-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。